TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive “Too much [of NCI’s] planning is reactive rather than proactive. As a consequence, vision suffers.” July 7, 1995
TCL Archive NCI To Fund Study of Stomach Cancer In Poles, Polish Americans, In Warsaw And Chicago Areas April 17, 1992
TCL Archive NCI Implementing Changes In Organ Site Program, Directing Grant applications To NIH Study Sections October 15, 1982
